drugset / Trial / NCT06660498
Pomalidomide as an Immune-enhancing Agent for the Control of HIV
RandomizedParallel-groupTriple-blindTreatment
Summary
This study is designed to evaluate the safety and efficacy of pomalidomide in HIV-1-infected individuals on ART and to determine the impact of pomalidomide on virological control in people living with HIV during an analytical treatment interruption.
Timeline
- Start
- 2025-05-13
- Primary completion
- 2027-03-31
- Completion
- 2027-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pomalidomide | Other / unclassified | 2 mg | Oral |
| Comparator | Aspirin | Small molecule | 75 mg | — |